Hashemi Rafsanjani Mahmood Reza, Rahimi Rasoul, Heidari-Soureshjani Saeid, Darvishi Mohammad, Adeli Omid-Ali, Abbaszadeh Saber
Researcher and General Practitioner, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Department of Surgery, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Recent Pat Anticancer Drug Discov. 2024 Jan 26. doi: 10.2174/0115748928282686231221070441.
Hepatocellular Carcinoma (HCC) is a public health problem around the world. Several studies have investigated the association between statin use and the risk of HCC, however, more studies are needed in this field.
This systematic review and meta-analysis aimed to investigate the relationship between statin use and HCC risk.
Systematic searches of Web of Science, Scopus, PubMed, Cochrane, Science Direct, and Embase were conducted for studies published between 1980 and September 2023. Metaanalyses were performed using Stata 15 with a significance level of 0.05.
The search retrieved 8,125 articles, of which 40 were included in the meta-analysis after applying eligibility criteria. The total sample was 5,732,948 participants, including 68,698 HCC cases. Statin use was associated with a 44% lower risk of HCC compared to non-use (RR 0.56, 95% CI 0.50-0.63, p < 0.001). The RR was 0.54 (0.42-0.69) in American countries, 0.52 (0.44-0.62) in Asian countries, and 0.63 (0.48-0.84) in European countries. The RR was 0.50 (0.42-0.60) in studies with a mean age <50 years and 0.61 (0.53-0.70) in studies with a mean age ≥50 years. No evidence of publication bias was found (Begg's test p = 0.718).
This meta-analysis found statin use is associated with a significantly lower HCC risk. Statins may be a promising preventive intervention against HCC.
肝细胞癌（HCC）是一个全球性的公共卫生问题。多项研究调查了他汀类药物使用与HCC风险之间的关联，然而，该领域仍需要更多研究。
本系统评价和荟萃分析旨在研究他汀类药物使用与HCC风险之间的关系。
对1980年至2023年9月发表的研究在Web of Science、Scopus、PubMed、Cochrane、Science Direct和Embase数据库中进行系统检索。使用Stata 15进行荟萃分析，显著性水平为0.05。
检索到8125篇文章，应用纳入标准后，40篇被纳入荟萃分析。总样本为5732948名参与者，包括68698例HCC病例。与未使用他汀类药物相比，使用他汀类药物与HCC风险降低44%相关（风险比[RR]0.56，95%置信区间[CI]0.50 - 0.63，p < 0.001）。在美国国家，RR为0.54（0.42 - 0.69）；在亚洲国家，RR为0.52（0.44 - 0.62）；在欧洲国家，RR为0.63（0.48 - 0.84）。在平均年龄<50岁的研究中，RR为0.50（0.42 - 0.60）；在平均年龄≥50岁的研究中，RR为0.61（0.53 - 0.70）。未发现发表偏倚的证据（Begg检验p = 0.718）。
该荟萃分析发现使用他汀类药物与显著降低的HCC风险相关。他汀类药物可能是一种有前景的HCC预防干预措施。
